Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Maryland Tech Journal.
Press releases published on May 8, 2025

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
– WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – – First patient dosed in the Phase 1b/2 clinical trial of WTX-330, seeking to build on the clinical activity and tolerability …

Aduro Clean Technologies and Cleanfarms Sign Memorandum of Understanding to Collaborate on Development of Commercial Pathway for Challenging Agricultural Plastics
LONDON, Ontario, May 08, 2025 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower-value feedstocks, like waste …

Shock Top: A Bold Rebrand for a Craft Beer Icon
PORTLAND, Ore., May 08, 2025 (GLOBE NEWSWIRE) -- Shock Top, a craft beer icon and brand by Tilray Brands, Inc. company (NASDAQ: TLRY and TSX: TLRY), known for its bold flavors and unfiltered wheat ales, today announced a transformative rebrand. With …

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025 CLN-978 expands into Sjögren’s disease; Phase 1 study in active, moderate to severe patients …

Ligand Reports First Quarter 2025 Financial Results
First quarter performance driven by strong portfolio royalty revenue growth of 44% Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences Reiterating 2025 financial guidance of $ …

Syndax Announces Participation in May Investor Conferences
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as …

Aptose Reports First Quarter 2025 Results
SAN DIEGO and TORONTO, May 08, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat …

Rapport Therapeutics Reports First Quarter 2025 Financials and Provides Business Update
RAP-219 Phase 2a trial in patients with refractory focal epilepsy remains on track with topline results expected in the third quarter of 2025 RAP-219 Phase 2a trial in patients with bipolar mania remains on track to commence in the third quarter of 2025, …

Entrada Therapeutics Reports First Quarter 2025 Financial Results
– Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company remains on track to initiate ELEVATE-44-201 …

Verano Announces First Quarter 2025 Financial Results
CHICAGO, May 08, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) ("Verano" or the "Company"), a leading multi-state cannabis company, today announced its financial results for the first quarter ended March 31, 2025, which were …

Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.
-Adds BFS platform technology to provide large-scale production capacity for sterile drug dosage forms, including injectables, ophthalmics and inhalation -Expands Amneal’s extensive domestic pharmaceutical manufacturing footprint BRIDGEWATER, N.J., May 08, …

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
- Multiple Catalysts in Immuno-Inflammatory Indications Anticipated in 2025 and 2026 - - Expected Cash Runway Extended Through the First Half of 2028 - - Phase 2 Results Received to Date from Chinese Partner CTTQ Provide Clinical Evidence of Enhanced …

Biconomy.com Accelerates Toward Global Dominance in Crypto Trading
DUBAI, United Arab Emirates, May 08, 2025 (GLOBE NEWSWIRE) -- Biconomy.com Exchange has unveiled an ambitious strategic roadmap aimed at securing its position as the dominant force in global crypto trading. With a laser focus on unlocking financial access …

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update
Awaiting FDA action on YUTREPIA™ NDA with a PDUFA goal date of May 24, 2025 District Court dismissed cross claim filed by United Therapeutics challenging PH-ILD amendment Fully enrolled Cohort A of ASCENT study in patients with PH-ILD Further strengthened …

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress
--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 -- --With positive Phase 2b …

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%
Consolidated net revenue of € 680.0 million in the first quarter of 2025, +11.9% or +7.2% on a like-for-like basis(3) and at constant exchange rates (CER) EBITDA(1) of € 270.2 million, +10.7%, margin on revenue of 39.7% Adjusted net income(2) of € …

CLEAR Announces First Quarter 2025 Financial Results
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Clear Secure, Inc. (NYSE: YOU), the secure identity platform, has posted a shareholder letter containing its 2025 first quarter financial results on its Investor Relations website at https://ir.clearme.com. CLEAR …

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
SAN MATEO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today reported financial results …

JuicyChat.AI Introduces NSFW AI Image Generator to Boost Immersive Chats
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- JuicyChat.AI has introduced its NSFW AI Image Generator, a groundbreaking tool that elevates chatting with vibrant, AI-generated visuals. Seamlessly integrated into the platform, this feature combines text and …

NewBiologix Licenses Xcell-Eng-HEK293 Cell Line to ReciBioPharm for Development and Manufacture of Adeno-Associated Virus (AAV) Therapeutics
Provides ReciBioPharm’s customers with access to NewBiologix’s Xcell-Eng-HEK293 cell lines for advanced therapies Complements and further expands ReciBioPharm’s AAV offering Achieves industry-leading results across multiple AAV programs LAUSANNE, …